These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
392 related articles for article (PubMed ID: 8687144)
1. TPS and CA 15.3 serum values as a guide for treating and monitoring breast cancer patients. Giai M; Roagna R; Ponzone R; Biglia N; Sgro L; Perona M; Sismondi P Anticancer Res; 1996; 16(2):875-81. PubMed ID: 8687144 [TBL] [Abstract][Full Text] [Related]
2. Determination of serum tumor markers TPS and CA 15-3 during monitoring of treatment in metastatic breast cancer patients. Schuurman JJ; Bong SB; Einarsson R Anticancer Res; 1996; 16(4B):2169-72. PubMed ID: 8694538 [TBL] [Abstract][Full Text] [Related]
3. Clinical value of serum tumour markers TPA, TPS, TAG 12, CA 15-3 and MCA in breast cancer diagnosis; results from a prospective study. Eskelinen M; Hippeläinen M; Kettunen J; Salmela E; Penttilä I; Alhava E Anticancer Res; 1994; 14(2B):699-703. PubMed ID: 8010729 [TBL] [Abstract][Full Text] [Related]
4. Tissue polypeptide specific antigen and cancer associated serum antigen in the follow-up of ovarian cancer. Sliutz G; Tempfer C; Kainz C; Mustafa G; Gitsch G; Koelbl H; Biegelmayer C Anticancer Res; 1995; 15(3):1127-9. PubMed ID: 7645936 [TBL] [Abstract][Full Text] [Related]
5. Use of TPS and CA 15-3 assays for monitoring chemotherapy in metastatic breast cancer patients. Einarsson R; Lindman H; Bergh J Anticancer Res; 2000; 20(6D):5089-93. PubMed ID: 11326674 [TBL] [Abstract][Full Text] [Related]
6. [Elevation of serum Ca 15-3 antigen: an early indicator of distant metastasis from breast cancer. Retrospective analysis of 733 cases]. Wojtacki J; Kruszewski WJ; Sliwińska M; Kruszewska E; Hajdukiewicz W; Sliwiński W; Rolka-Stempniewicz G; Góralczyk M; Leśniewski-Kmak K Przegl Lek; 2001; 58(6):498-503. PubMed ID: 11816740 [TBL] [Abstract][Full Text] [Related]
7. Serum tumour markers CEA, AFP, CA 15-3, TPS and Neu in diagnosis of breast cancer. Eskelinen M; Kataja V; Hämäläinen E; Kosma VM; Penttilä I; Alhava E Anticancer Res; 1997; 17(2B):1231-4. PubMed ID: 9137478 [TBL] [Abstract][Full Text] [Related]
8. Clinical value of TPS, CEA and CA 15-3 in breast cancer patients. Blijlevens NM; Oosterhuis WP; Oosten HR; Mulder NH Anticancer Res; 1995; 15(6B):2711-6. PubMed ID: 8669851 [TBL] [Abstract][Full Text] [Related]
9. [Clinical study of serum tissue polypeptide-specific antigen in breast cancer]. Zheng H; He BF; Luo RC; You CX; Mai GF; Lu HF Di Yi Jun Yi Da Xue Xue Bao; 2003 Aug; 23(8):823-5. PubMed ID: 12919909 [TBL] [Abstract][Full Text] [Related]
10. Serum tissue polypeptide specific antigen (TPS) in breast cancer patients: comparison with CA 15.3 and CEA. Willsher PC; Beaver J; Blamey RW; Robertson JF Anticancer Res; 1995; 15(4):1609-11. PubMed ID: 7654057 [TBL] [Abstract][Full Text] [Related]
11. A prospective study of tissue polypeptide specific antigen (TPS) in breast cancer diagnosis. Eskelinen M; Hippeläinen M; Salmela E; Paajanen H; Alhava E; Syrjänen K Anticancer Res; 1992; 12(6B):2033-6. PubMed ID: 1295446 [TBL] [Abstract][Full Text] [Related]
12. Preoperative CA 15-3 concentrations predict outcome of patients with breast carcinoma. Shering SG; Sherry F; McDermott EW; O'Higgins NJ; Duffy MJ Cancer; 1998 Dec; 83(12):2521-7. PubMed ID: 9874458 [TBL] [Abstract][Full Text] [Related]
13. Clinical evaluation of new serum tumor markers CA M26 and CA M29 in patients with primary breast cancer. Eskelinen M; Tikanoja S; Brown J Anticancer Res; 1990; 10(4):959-62. PubMed ID: 2382995 [TBL] [Abstract][Full Text] [Related]
14. [Detection of serum S100 protein and tissue polypeptide-specific antigen for diagnosis and treatment of breast cancer]. Luo RC; He XB; Cai HB; Li AM Di Yi Jun Yi Da Xue Xue Bao; 2004 Jan; 24(1):102-4. PubMed ID: 14724113 [TBL] [Abstract][Full Text] [Related]
15. Pretreatment values of serum CA 15-3 antigen related to prognostic factors in breast cancer patients. Wojtacki J; Dziewulska-Bokiniec A; Kowalski DM; Zółtowska A; Ciesielski D; Suszko M Neoplasma; 1996; 43(4):225-9. PubMed ID: 8931745 [TBL] [Abstract][Full Text] [Related]
16. [Diagnostic value of combined detection of TPS, CA153 and CEA in breast cancer]. Zheng H; Luo RC Di Yi Jun Yi Da Xue Xue Bao; 2005 Oct; 25(10):1293-4, 1298. PubMed ID: 16234113 [TBL] [Abstract][Full Text] [Related]
17. [Initial experiences with CA-15-3 determination in the serum of patients with breast cancer]. Bartel U; Johannsen B; Reiss H; Elling D Zentralbl Gynakol; 1989; 111(21):1417-24. PubMed ID: 2557715 [TBL] [Abstract][Full Text] [Related]
18. Usefulness of CEA, TPA, GICA, CA 72.4, and CA 195 in the Diagnosis of primary colorectal cancer and at its relapse. Nicolini A; Caciagli M; Zampieri F; Ciampalini G; Carpi A; Spisni R; Colizzi C Cancer Detect Prev; 1995; 19(2):183-95. PubMed ID: 7750106 [TBL] [Abstract][Full Text] [Related]
19. Importance of CEA and CA 15-3 during disease progression in metastatic breast cancer patients. Laessig D; Nagel D; Heinemann V; Untch M; Kahlert S; Bauerfeind I; Stieber P Anticancer Res; 2007; 27(4A):1963-8. PubMed ID: 17649806 [TBL] [Abstract][Full Text] [Related]
20. Serum tissue polypeptide specific antigen (TPS) in locoregional failure and distant metastasis of cervical carcinoma. Pattaranutaporn P; Chansilpa Y; Ieumwananonthachai N; Sukkasem M J Med Assoc Thai; 2000 Sep; 83(9):1011-5. PubMed ID: 11075966 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]